October 14, 2019

Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer

Key Points

Key points are not available for this paper at this time.

Abstract

PGK1 is a decisive oncogene in patients with SMAD4-negative PDAC and can be a target for the development of a therapeutic strategy for SMAD4-negative PDAC.

Bookmark

Cite This Study

Liang et al. (Mon,) studied this question.

synapsesocial.com/papers/69d80f7966a29169b4bee006 https://doi.org/https://doi.org/10.1136/gutjnl-2018-317163

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States2014 · 7,254 citations
2Crystal Structures of Substrates and Products Bound to the Phosphoglycerate Kinase Active Site Reveal the Catalytic Mechanism1998 · 84 citations
3Protein kinase activity of the glycolytic enzyme PGK1 regulates autophagy to promote tumorigenesis2017 · 112 citations
4Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial2015 · 240 citations
5Differentiation plasticity regulated by TGF-β family proteins in development and disease2007 · 374 citations